{"id":"W2944626596","doi":"10.1158/1538-7445.sabcs18-p6-18-05","title":"Abstract P6-18-05: First-line ribociclib + endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled efficacy analysis","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Letrozole; Fulvestrant; Internal medicine; Anastrozole; Goserelin; Clinical endpoint; Breast cancer; Placebo; Cancer; Oncology; Palbociclib; Aromatase inhibitor; Metastatic breast cancer; Gastroenterology; Clinical trial; Estrogen receptor; Tamoxifen; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01664458,0.002487921,0.007279574,0.00194103,0.0002162942,0.002061311,0.0008921679,0.001194962,0.005512107],"category_scores_gemma":[0.01028593,0.0007398328,0.02111705,0.001810312,0.0005433935,0.001219013,0.001119119,0.001657909,0.0006598579],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007703013,"about_ca_system_score_gemma":0.0009834662,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007349986,"about_ca_topic_score_gemma":0.001132045,"domain_scores_codex":[0.9901036,0.006994307,0.0009646635,0.0009800955,0.0007213491,0.0002359257],"domain_scores_gemma":[0.9941817,0.002827615,0.001832143,0.0004720066,0.0004128706,0.000273609],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.402519,0.0005325605,0.007158731,0.01262869,0.5411314,0.00008941082,0.00004113641,0.002318816,0.002170061,0.000148739,0.002408473,0.02885308],"study_design_scores_gemma":[0.2197328,0.02568441,0.03241428,0.0009413444,0.7109621,0.0002024297,0.00006069302,0.003293283,0.001288397,0.000497478,0.004842762,0.00008013046],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5825756,0.34454,0.01930392,0.001898034,0.001912159,0.008175302,0.03261565,0.00111769,0.007861586],"genre_scores_gemma":[0.9598035,0.02194374,0.004044204,0.001007904,0.0007909962,0.003172888,0.007409034,0.00009457001,0.001733145],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01664458,"threshold_uncertainty_score":0.08802599,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04112823362356666,"score_gpt":0.401301505145901,"score_spread":0.3601732715223343,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}